Which generation of targeted drug is Asiminib? What is its place in leukemia treatment?

Asciminib is a new type of targeted drug. It is an innovative drug after the first generation tyrosine kinase inhibitors (TKIs). Its uniqueness is that it does not directly bind to the kinase structure of the BCR-ABL fusion protein like traditional TKIs drugs, but selectively binds to a new binding site of ABL kinase - called Myristoyl. pocket to inhibit the activity of BCR-ABL. This new mechanism of action makes Asiminib an important advance in the treatment of chronic myelogenous leukemia (CML), especially in patients who have developed resistance or intolerance to traditional TKIs. Asiminib provides new therapeutic hope.

The mechanism of action of Asiminib is different from that of early TKIs such as Imatinib and Dasatinib. Traditional TKIs mainly inhibit the activity of BCR-ABL by binding to its kinase domain, while Asiminib inhibits its activity through Myristoyl. Pocket inhibits the function of BCR-ABL kinase. This unique mode of action allows Asiminib to bypass the resistance mutations of traditional TKIs. Especially for those CML patients with mutations such as T315I, Asiminib shows strong efficacy. This also makes aceminib gradually gain more and more attention as an effective second-line or third-line treatment drug in clinical practice.

Asiminib’s status in the treatment of leukemia continues to increase, especially in the treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is a malignant blood disease derived from hematopoietic stem cells. Patients have an abnormal increase in white blood cells. Since TKIs such as imatinib were used in the treatment of CML, the survival rate of patients has greatly improved. However, with long-term treatment, some patients may develop drug resistance or have adverse reactions to traditional drugs, especially those with specific genetic mutations. At this time, the emergence of acemini provides new treatment options for these patients.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib